Targeting key genes in the LTM pathway, such as HSPA5 and CTNNB1, could offer novel approaches to enhance immune cell infiltration and restore immune surveillance in HPV-positive cervical cancer. The gene discussed is HSPA5; the disease is cervical cancer.